Stanford inventors have discovered that applying a hydrogel containing an inhibitor of mechanotransduction pathways on top of a skin graft reduces scarring and promotes healing after repair of traumatic injuries like severe burn wounds.
A common hurdle for many drug delivery applications is getting the desired compounds to the targeted cells or receptors. Additional barriers of achieving the therapeutic drug concentration and necessary drug diffusion are also present even after successful targeted delivery.
Recent studies have linked microglia damage to various neurodegenerative and aging brain diseases. Relatedly, bone marrow transplantation has been shown to result in incorporation of macrophages into the brain, but the incorporation is variable, slow and inefficient.
Stanford researchers at the Thakor Lab have developed methods for kidney tissue regeneration using pulsed focused ultrasound (pFUS) therapy with mesenchymal stromal cells (MSCs) and/or MSC-derived extracellular vesicles (e.g., exosomes or microvesicles).
The emergence of SARS-CoV-2 variants during the COVID-19 pandemic has demonstrated a need for broad immunization, such as provided by multivalent vaccines.
Researchers in the Appel lab have developed hydrogels for tumor inoculation that improve precision and statistical power in preclinical mouse models of cancer.
Stanford researchers have applied large-scale proteomic platforms to identify biomarkers that can be used to diagnose uveal melanoma and subtype eye tumors according to their gene expression profile (GEP) class or PRAME status.
Stanford researchers are developing an improved prophylactic against pancreatitis caused by endoscopic retrograde cholangiopancreatography (ERCP), by targeting two key inflammatory pathways.
A team of researchers at Stanford have developed a hydrogel that delivers a scar-reducing focal adhesion kinase inhibitor (FAK-I) to skin grafts and donor sites.
Researchers in the laboratories of Prof. Stanley Cohen and Prof Tzu-Hao Cheng have discovered that Supt4h is a potential therapeutic target for reducing toxicity and restoring the functionality of deleterious proteins in Huntington's (HD) and other polyQ diseases.
Dr. Stanley Cohen and colleagues have identified small molecular compounds that may be useful in the treatment of nucleotide repeat diseases. A well-known nucleotide repeat disorder is Huntington's disease.
Collagen-based hydrogels behave similarly to the native tissue microenvironment, thus are widely used as scaffolds for encapsulating cells or molecules like growth factors. Collagen solution is an injectable liquid until it crosslinks at 37 C and physiological pH.
Tracking in vivo cell distribution, migration, and engraftment using conventional techniques including MRI, PET/CT and conventional optical imaging is often hindered by low resolution, radioactive risks, and limited tissue penetration depth.